Do Utility Values and Willingness to Pay Suitably Reflect Health Outcome in Hip and Knee Osteoarthritis? A Comparative Analysis with the WOMAC Index

Journal of Rheumatology

Volumn 30, Issue 11, 2003, Pages 2452-2459

  Ethgen, Olivier ^b   Tancredi, Annalisa ^b   Lejeune, Eric ^b   Kvasz, Angela ^b   Zegels, Brigitte ^b   Reginster, Jean Yves ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b NONE

Author keywords

Osteoarthritis; Time trade off; Willingness to pay; WOMAC

Indexed keywords

ANTIRHEUMATIC AGENT;

ADULT; AGED; ARTHRALGIA; CONVALESCENCE; CORRELATION ANALYSIS; DISEASE SEVERITY; EDUCATION; FEMALE; HEALTH CARE COST; HIP OSTEOARTHRITIS; HUMAN; INTERVIEW; JOINT FUNCTION; JOINT STIFFNESS; KNEE OSTEOARTHRITIS; KRUSKAL WALLIS TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL FEE; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SOCIAL STATUS; SOCIOECONOMICS; STANDARD; TREATMENT OUTCOME;

AGED; ANTI-INFLAMMATORY AGENTS; CHOICE BEHAVIOR; COST-BENEFIT ANALYSIS; DISABILITY EVALUATION; DRUG COSTS; FEASIBILITY STUDIES; FEMALE; FINANCING, PERSONAL; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; SOCIAL CLASS; TREATMENT OUTCOME;

EID: 0242524364     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Watson M. Management of patients with osteoarthritis. Pharm J 1997;259:296-7.
2. Reginster JY. The prevalence and burden of arthritis. Rheumatology Oxford 2002;41 Suppl 1:3-6.
3. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-99.
4. Kelsey JL, Hochberg MC. Epidemiology of chronic musculoskeletal disorders. Ann Rev Public health 1988;9:379-401.
5. Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum 1998;41:1343-55.
6. Badley EM, Wang PP. Arthritis and the aging population: projections of arthritis prevalence in Canada 1991 to 2031. J Rheumatol 1998;25:138-44.
7. Lanes SF, Lanza LL, Radensky PW, et al. Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a management care setting: the importance of drug and surgery costs. Arthritis Rheum 1997;40:1475-81.
8. Badley EM. The effects of osteoarthritis on disability and health care use in Canada. J Rheumatol 1995;22 Suppl 43:19-22.
9. MacLean CH, Knight K, Brook RH, et al. Costs attributable to osteoarthritis. J Rheumatol 1998;25:2213-8.
10. Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989;27 Suppl 3:S217-32.
11. Bellamy N. WOMAC Osteoarthritis index. A user's guide. London, Canada: University of Western Ontario; 1995.
12. Zhao SZ, McMillen JI, Markenson JA, et al. Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib. Pharmacotherapy 1999;19:1269-78.
13. Ehrich EW, Bolognese JA, Watson DJ, et al. Effect of Rofecoxib therapy on measures of health-related quality of life in patients with osteoarthritis. Am J Managed Care 2001;7:609-16.
14. Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001;357:251-6.
15. Rorareck CH, Bourne RB, Laupacis A, et al. A double-blind study of 250 cases comparing cemented with cementless total hip arthroplasty. Clin Orthop 1994;298:156-64.
16. Kreibich DN, Vaz M, Bourne RB, et al. What is the best way of assessing outcome after total knee replacement. Clin Orthop 1996;331:221-5.
17. Fortin PR, Clarke AE, Joseph L, et al. Outcomes of total hip and knee replacement. Preoperative functional status predicts outcomes at six months after surgery. Arthritis Rheum 1999;42:1722-8.
18. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for economic evaluation of health care programs. 2nd ed. Oxford: Oxford Medical Publications; 1987.
19. Blumenschein K, Johannesson M. Incorporating quality of life changes into economic evaluations of health care: an overview. Health Policy 1996;36:155-66.
20. Jonsson B. Quality of life and health economics: where is the link? Scand J Gastroenterol 1996;31 Suppl 221:33-6.
21. von Neumann J, Morgenstern O. Theory of games and behavior. Princeton: Princeton University Press; 1953.
22. Torrance GW, Thomas WM, Sackett DL. A utility maximization model for evaluation of health care programs. Health Services Res 1972;7:118-33.
23. Bala MV, Mauskopf JA, Wood LL. Willingness to pay as a measure of health benefits. Pharmacoeconomics 1999;15:9-18.
24. Gafni A. Willingness to pay in the context of an economic evaluation of healthcare programs: theory and practice. Am J Managed Care 1997;3 Suppl:S21-32.
25. Hanneman WM. Valuing the environment through contingent valuation. J Economic Perspectives 1994;8:19-43.
26. Berwick DM, Weinstein MC. What do patients value? Willingness to pay for ultrasound in normal pregnancy. Med Care 1985; 23:881-93.
27. Johannesson M, Johansson PO, Jönsson B. Economic evaluation of drug therapy. A review of the contingent valuation method. Pharmacoeconomics 1992;1:325-37.
28. Hyland ME. Quality of life measures as providers of information on value-for-money of health interventions. Comparison and recommendations for practice. Pharmacoeconomics 1997;11:19-31.
29. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Arthritis Rheum 1986;29:1039-49.
30. Altman R, Alarcon GC, Appelrouth D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991;34:505-14.
31. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-40.
32. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically-important patient-relevant outcomes following total hip or knee arthroplasty in osteoarthritis. J Orthop Rheumatol 1988;1:95-108.
33. Bellamy N, Kean WF, Buchanan WW, Gerecz-Simon E, Campbell J. Double blind randomized controlled trial of sodium meclofenamate (Meclomen) and diclofenac sodium (Voltaren): post validation reapplication of the WOMAC Osteoarthritis Index. J Rheumatol 1992;19:153-9.
34. Direction de la Surveillance de la Santé. Indicateurs de santé 1996. Brussels: Ministère de la Communauté Française. Direction de la Surveillance de la Santé; 1996:35.
35. Johannesson M, Johansson PO, Kristrom B, et al. Willingness to pay for antihypertensive therapy: further results. J Health Econ 1993;12:95-108.
36. Johansson PO. Evaluating health risks: an economic approach. Cambridge: Cambridge University Press; 1995.
37. Quataert P, Van Oyen H, Tafforeau J, et al. Health Interview Survey, 1997. Protocol for the selection of households and respondents. S.P.H/EPISERIE No. 12. Brussels: Scientific Institute of Public Health; 1997.
38. Gafni A. Using willingness-to-pay as a measure of benefits: what is the relevant question to ask in the context of public decision making? Med Dec Making 1991;29:1246-52.
39. Thompson MS, Leighton Read J, Liang M. Feasibility of willingness-to-pay measurement in chronic arthritis. Med Dec Making 1984;4:195-215.
40. Johannesson M, Jönsson B, Karlsson G. Outcome measurement in economic evaluation. Health Econ 1996;5:279-96.
41. Bleichrodt H, Johannesson M. An experimental test of a theoretical foundation for rating-scale valuations. Med Dec Making 1997;17:208-16.
42. Cross MJ, March LM, Lapsley HM, et al. Determinants of willingness to pay for hip and knee joint replacement surgery for osteoarthritis. Rheumatol 2000;39:1242-8.
43. Blumenschein K, Johannesson M. Relationship between quality of life instruments, health state utilities, and willingness to pay in patients with asthma. Ann Allergy Asthma Immunol 1998;80:189-94.
44. Lundberg L, Johannesson M, Silverdahl M, et al. Quality of life, health state utilities and willingness to pay with psoriasis and atopic eczema. Br J Dermatol 1999;141:1067-75.
45. Bosch JL, Hunink MGM. The relationship between descriptive and valuational quality-of-life measures in patients with intermittent claudication. Med Dec Making 1996;16:217-25.
46. O'Brien B, Viramontes JL. Willingness to pay: a valid and reliable measure of health state preference? Med Dec Making 1994; 14:289-97.
47. Bala MV, Wood LL, Zarkin GA, et al. Valuing outcomes in health care: A comparison of willingness to pay and quality-adjusted life years. J Clin Epidemiol 1998;51:667-76.
48. Cunningham SJ, Hunt NP. Relationship between utility values and willingness to pay in patients undergoing orthognathic treatment. Community Dental Health 2000;17:92-6.
49. Thompson MS. Willingness to pay and accept risks to cure chronic disease. Am J Public Health 1986;76:392-6.
50. Rothfuss J, Mau W, Zeider H, et al. Socioeconomic evaluation of rheumatoid arthritis and osteoarthritis: a literature review. Semin Arthritis Rheum 1997;25:771-9.
51. Ferraz MB, Maetzel A, Bombardier C. A summary of economic evaluations published in the field of rheumatology and related disciplines. Arthritis Rheum 1997;40:1587-93.
52. Slothuus U, Brooks RG. Willingness to pay in arthritis: a Danish contribution. Rheumatol 2000;39:791-9.
53. Liljas B, Lindgren B. On individual preferences and aggregation in economic evaluation in healthcare. Pharmacoeconomics 2001;19:323-35.
54. Johannesson M, Jönsson B. Economic evaluation in health care: Is there a role for cost-benefit analysis. Health Policy 1991;17:1-23.
55. Burrows C, Brown K. Are any numbers better than no numbers? The sorry state of willingness-to-pay and some major methodological shortcomings. Australian Health Rev 1992; 15:135-44.
56. Donaldson C. Valuing the benefits of publicly-provided health care: does "ability to pay" preclude the use of "willingness to pay"? Soc Sci Med 1999;49:551-63.